Perfint Healthcare launches MAXIO – a robotic tumour ablation tool
Perfint Healthcare Corporation, based in Chennai, India and USA, has launched MAXIO, the company’s integrated planning, navigation and robotic targeting system for CT guided tumour ablation. The new robot is a first-of-its-kind advanced intelligent tool that will change the way healthcare experts approach interventional oncology and cancer care.
Perfint Healthcare is an innovative medical device company focused on the development of robotic assisted technologies that simplify complex procedures and improve the standard of care provided to patients in need of interventional therapies.
MAXIO combines tumour visualisation in 3D and procedure planning with robotic targeting that helps clinicians achieve consistent procedure quality. Nandakumar Subburaman, CEO and founder of Perfint Healthcare stated, “Interventional oncology and in specific tumour ablation is rapidly becoming an effective alternate to surgical treatment for cancer, globally. MAXIO brings the practice of interventional oncology to a whole new level.” He added, “Our aim was to create a solution that would make life-saving ablation procedures available to a greater number of cancer sufferers. We realised that the complex techniques used by interventional radiologists would have to be made simpler, and more predictable. That’s what we’ve done with MAXIO.”
MAXIO was developed through support under the BIPP scheme of the Department of Biotechnology and meets the best-in-class standards globally. The product complies with CE marking requirements.
MAXIO’s workflow and Robotic targeting will make it easy for large scale adoption of tumour ablation in highly populous societies such as in India, China, Indonesia and Latin America – where there is an urgent need to create high quality cancer care infrastructure, quickly and at a low cost.